↓ Skip to main content

Dove Medical Press

Update on the management of cirrhosis – focus on cost-effective preventative strategies

Overview of attention for article published in ClinicoEconomics and Outcomes Research: CEOR, April 2013
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (66th percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
1 X user
patent
2 patents

Citations

dimensions_citation
40 Dimensions

Readers on

mendeley
87 Mendeley
citeulike
1 CiteULike
Title
Update on the management of cirrhosis – focus on cost-effective preventative strategies
Published in
ClinicoEconomics and Outcomes Research: CEOR, April 2013
DOI 10.2147/ceor.s30675
Pubmed ID
Authors

Guy W Neff, Nyingi Kemmer, Christopher Duncan, Angel Alsina

Abstract

Cirrhosis is a chronic liver disease stage that encompasses a variety of etiologies resulting in liver damage. This damage may induce secondary complications such as portal hypertension, esophageal variceal bleeding, spontaneous bacterial peritonitis, and hepatic encephalopathy. Screening for and management of these complications incurs substantial health care costs; thus, determining the most economical and beneficial treatment strategies is essential. This article reviews the economic impact of a variety of prophylactic and treatment regimens employed for cirrhosis-related complications. Prophylactic use of β-adrenergic blockers for portal hypertension and variceal bleeding appears to be cost-effective, but the most economical regimen for treatment of initial bleeding is unclear given that cost comparisons of pharmacologic and surgical regimens are lacking. In contrast, prophylaxis for spontaneous bacterial peritonitis cannot be recommended. Standard therapy for spontaneous bacterial peritonitis includes antibiotics, and the overall economic impact of these medications depends largely on their direct cost. However, the potential development of bacterial antibiotic resistance and resulting clinical failure should also be considered. Nonabsorbable disaccharides are standard therapies for hepatic encephalopathy; however, given their questionable efficacy, the nonsystemic antibiotic rifaximin may be a more cost-effective, long-term treatment for hepatic encephalopathy, despite its increased direct cost, because of its demonstrated efficacy and prevention of hospitalization. Further studies evaluating the cost burden of cirrhosis and cirrhosis-related complications, including screening costs, the cost of treatment and maintenance therapy, conveyance to liver transplantation, liver transplantation success, and health-related quality of life after transplantation, are essential for evaluation of the economic burden of hepatic encephalopathy and all cirrhosis-related complications.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 87 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Russia 1 1%
Denmark 1 1%
Germany 1 1%
Unknown 84 97%

Demographic breakdown

Readers by professional status Count As %
Researcher 15 17%
Student > Master 13 15%
Other 9 10%
Student > Ph. D. Student 8 9%
Student > Bachelor 7 8%
Other 17 20%
Unknown 18 21%
Readers by discipline Count As %
Medicine and Dentistry 38 44%
Pharmacology, Toxicology and Pharmaceutical Science 7 8%
Agricultural and Biological Sciences 4 5%
Nursing and Health Professions 3 3%
Engineering 3 3%
Other 10 11%
Unknown 22 25%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 August 2023.
All research outputs
#8,296,578
of 25,457,858 outputs
Outputs from ClinicoEconomics and Outcomes Research: CEOR
#193
of 525 outputs
Outputs of similar age
#69,432
of 213,192 outputs
Outputs of similar age from ClinicoEconomics and Outcomes Research: CEOR
#5
of 8 outputs
Altmetric has tracked 25,457,858 research outputs across all sources so far. This one has received more attention than most of these and is in the 66th percentile.
So far Altmetric has tracked 525 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.0. This one has gotten more attention than average, scoring higher than 62% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 213,192 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 66% of its contemporaries.
We're also able to compare this research output to 8 others from the same source and published within six weeks on either side of this one. This one has scored higher than 3 of them.